<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>"Later <z:hpo ids='HP_0003674'>onset</z:hpo>" of systemic <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> (SM) has been associated with a poorer prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>We examined clinical and laboratory findings, associated disorders, and survival in an older <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> population </plain></SENT>
<SENT sid="2" pm="."><plain>After receiving Mayo Clinic Institutional Review Board approval, we identified 42 patients aged 70 years and older at the time of diagnosis of SM </plain></SENT>
<SENT sid="3" pm="."><plain>Associated disorders, cytogenetic abnormalities, laboratory findings, and survival were recorded </plain></SENT>
<SENT sid="4" pm="."><plain>Only 10 patients had no associated <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorder</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Single or multiple chromosomal abnormalities, exclusive of the KIT Asp816Val mutation, were detected in eight patients (19%) </plain></SENT>
<SENT sid="6" pm="."><plain>KIT Asp816Val mutation was present in 14 patients, negative in three, and not tested in 25 </plain></SENT>
<SENT sid="7" pm="."><plain>Slight to marked bone marrow hypercellularity was observed in 33 patients (79%) </plain></SENT>
<SENT sid="8" pm="."><plain>Concurrent hematologic abnormalities included <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 7), <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> (n = 1), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; n = 7), <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> (n = 7), <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (n = 1), <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> (n = 1), <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (n = 1), B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1), and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (n = 4) </plain></SENT>
<SENT sid="9" pm="."><plain>Eight patients had a <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorder</z:e> that preceded the diagnosis of SM </plain></SENT>
<SENT sid="10" pm="."><plain>Tryptase levels were elevated in 38 of 39 patients tested </plain></SENT>
<SENT sid="11" pm="."><plain>Survival from the diagnosis of SM was poor for patients with associated <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:hpo ids='HP_0001909'>leukemias</z:hpo>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>In conclusion, patients with SM diagnosed at age 70 or older have an increased risk of secondary <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> and abnormal laboratory findings </plain></SENT>
<SENT sid="13" pm="."><plain>Cytogenetic abnormalities are common, and survival is short in many SM patients with associated <z:hpo ids='HP_0001909'>leukemias</z:hpo>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, or <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> </plain></SENT>
</text></document>